Summary
The AI response appears to evaluate benzyl alcohol/neonate/premature-infant labeling, but it also makes multiple generalized corticosteroid claims and an active-ingredient mismatch versus the label excerpt. Because only partial label content is actually provided and several statements are not supported by the supplied label excerpts, overall alignment is poor.
Category Scores
Accurate Statements
The product contains benzyl alcohol after mixing/reconstitution.
DESCRIPTION excerpts: 'Also contains benzyl alcohol' and note that after mixing as directed methylprednisolone contains benzyl alcohol.
Exposure to excessive amounts of benzyl alcohol has been associated with toxicity in neonates (e.g., hypotension, metabolic acidosis) and an increased incidence of kernicterus, particularly in small preterm infants.
WARNINGS excerpt: toxicity associated with excessive benzyl alcohol, 'particularly in neonates', and 'increased incidence of kernicterus, particularly in small preterm infants.'
There is a contraindication for use in premature infants when reconstituted with benzyl alcohol.
CONTRAINDICATIONS excerpt: '... reconstituted with benzyl alcohol, is contraindicated for use in premature infants.'
‘Gasping syndrome’ is described in pediatric use, including neonates, and is associated with benzyl alcohol dosages >99 mg/kg/day.
PRECAUTIONS—Pediatric Use excerpt: describes gasping syndrome and benzyl alcohol dosages >99 mg/kg/day in neonates.
Unsupported Statements
Methylprednisolone acetate is a corticosteroid medicine used to reduce inflammation.
The supplied label excerpts provided are for methylprednisolone sodium succinate for injection and do not support the generalized 'methylprednisolone acetate' description.
Methylprednisolone acetate is used to treat certain immune-related conditions / used for joint and inflammatory disorders / used for allergic and immune-mediated conditions / used for certain flare-ups where rapid reduction of inflammation is needed.
No FDA-approved indication text from the provided label excerpts supports these broad indication claims.
Methylprednisolone acetate is used in conditions where steroid injections are used.
The provided excerpts do not list indications or describe such usage; the claim is too generalized and unsupported by the supplied sections.
Methylprednisolone acetate can be administered by injection into a muscle / by injection into a joint space.
The provided label excerpts do not state route-of-administration specifics (IM/joint space).
Common risks/side effects of corticosteroids include increased risk of infection; corticosteroids can mask infection symptoms; corticosteroids can increase blood sugar; mood or sleep changes; stomach irritation; longer use increases ulcer risk; prolonged use can have bone effects.
None of these generalized adverse effect claims are supported by the supplied label excerpts.
Patients may be advised to avoid live vaccines while on steroid therapy; exact guidance on interactions and live vaccines depends on dose and duration and on the product’s prescribing information.
The supplied excerpts do not include interaction or vaccine guidance.
The label explicitly states the product is 'Methylprednisolone sodium succinate for injection, USP' and the active ingredient is methylprednisolone sodium succinate, USP.
This appears to be based on label context in the prompt, but the user-supplied label text excerpt content provided in this chat is insufficient to independently verify the stated match; additionally, earlier statements refer to 'methylprednisolone acetate' rather than sodium succinate, creating inconsistency.
Contradictions
Low
AI Statement
Methylprednisolone acetate is a corticosteroid medicine...
Label Reference
Provided label excerpts are for methylprednisolone sodium succinate for injection; no excerpts support methylprednisolone acetate.
Important Omissions
Boxed warnings, contraindications beyond premature infants with benzyl alcohol reconstitution, and any label-supported general corticosteroid precautions (infection risk, glycemic effects, GI effects, bone effects) relevant to the generalized safety statements made.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-supported elements in the provided excerpts relate to benzyl alcohol toxicity risk in neonates/premature infants and a specific contraindication; however, many additional generalized corticosteroid claims are not supported by the supplied excerpts, which reduces label alignment rather than directly demonstrating a specific unsafe instruction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple generalized claims about indications, routes, and corticosteroid adverse effects are not supported by the provided FDA label excerpts, and the response inconsistently refers to 'methylprednisolone acetate' while the cited label content is for 'methylprednisolone sodium succinate for injection.'
Suggested Improvement
Restrict statements to the exact label-supported content provided (benzyl alcohol presence after mixing, neonatal/premature toxicity warnings, 'gasping syndrome', kernicterus association, and the premature-infant contraindication). Remove or re-verify any generalized indication, route, interactions, vaccine, and broad corticosteroid side-effect claims against the actual label sections.